A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Leah Cliatt , Joanna Petrides
Corresponding author: Leah Cliatt, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Introduction
The COVID-19 pandemic sparked an interest in skincare with the closure of spas and salons. Skincare, one of TikTok's most popular dermatology-related hashtags, received hundreds of millions of views. The American Academy of Dermatology (AAD) sharedfacial cleansing recommendations; however, how many people follow them is unclear. Studies have shown a good daily facial cleansing andmoisturizing routine can increase microbiome diversityand skin hydration. This can be beneficial in conditions like psoriasis, eczema, and acne.
Purpose
The aim of the study is to assess how well people follow the AAD recommendations and evaluate any differences in this behavior by gender.
Methods
A 19-question survey was designed and administered utilizing Qualtrics. The questions included demographic information, facial cleansing practices, and motivation for skincare routine. The survey was distributed via Rowan Email and on various social media platforms (GroupMe, Instagram, etc.) to target the general population. The data was analyzed using SPSS.
Results
One hundred twenty-four responses were collected from 91 female-identifying and 33 male-identifying participants. There were statistically significant differences between genders for the use of non-alcoholic gentle cleanser (p<0.001), use of moisturizer after washing the face (p<0.001), washing the face after sweating (p<0.001), and using warm water (p=0.026). No statistically significant difference was seen for face washing occurrence between genders (p=0.098). Statistically significant differences were seen between genders for motivation: hygiene (p<0.001), beauty/anti-aging (p<0.001), and health (p=0.004).
Conclusion
Individuals who identify as female may be more likely to adhere to AAD facial skincare recommendations. This could be a result of self-reported motivations such as hygiene, beauty, and health.
Categories: Dermatology
Keywords: beauty, dermatologic agents, dermatology, face cleansing, face washing, female, hygiene, skin
Review began 11/19/2024
Review ended 12/12/2024
Published 12/16/2024
© Copyright 2024
Cliatt et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI: 10.7759/cureus.75810
Fan Yang1 Xinyuan Zhang2 Hua Wang1 Miao Guo1 Jinlong Zhang1 Xuejiao Feng3 Jiayi Yu3 Jiahui Yang3 Jinjin Zhu4 Yiyu Wang3
1 Research & Development Center, Mageline Biology Tech Co., Ltd, Wuhan, Hubei, China
2 Shanghai Skinshield Clinical Testing and Technological Research Ltd., Shanghai, China
3 Department of Dermatology, Air Force Medical Center, PLA, Beijing, China
4 Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China
Correspondence
Jinjin Zhu, Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, 430022, China.
Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Yiyu Wang, Department of Dermatology, Air Force Medical Center, PLA, Beijing, China.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2024 The Author(s). Skin Research and Technology published by John Wiley & Sons Ltd.
Background: The delicate periorbital region is susceptible to skin dehydration, wrinkles, and loss of elasticity. Thus, targeted and effective anti-aging interventions are necessary for the periorbital area.
Aim: To evaluate the efficacy and safety of a new anti-aging eye cream formulated with the active complex (Yeast/rice fermentation filtrate, N-acetylneuraminic acid, palmityl tripeptide-1, and palmitoyl tetrapeptide-7).
Methods: The cell viability and expressions of key extracellular matrix (ECM) components of the active complex were evaluated using a human skin fibroblast model. In the 12-week clinical trial, skin hydration, elasticity, facial photographs, and collagen density following eye cream application were assessed using Corneometer, Cutometer, VISIA, and ultrasound device, respectively. Dermatologists and participants evaluated clinical efficacy and safety at baseline, and after 4, 8, and 12 weeks.
Results: PCR and immunofluorescent analyses revealed that the active complex significantly stimulated fibroblast proliferation (p < 0.05) and markedly promote the synthesis of collagen and elastin. Clinical findings exhibited a substantial enhancement in skin hydration (28.12%), elasticity (18.81%), and collagen production (54.99%) following 12 weeks of eye cream application. Dermatological evaluations and participants’ assessments reported a significant improvement in skin moisture, roughness, elasticity, as well as fine lines and wrinkles by week 8.
Conclusion: The new anti-aging eye cream, enriched with the active complex, demonstrates comprehensive rejuvenating effects, effectively addressing aging concerns in the periorbital area, coupled with a high safety profile.
KEYWORDS
anti-aging, collagen, elastin, extracellular matrix, eye cream, wrinkle
Priscilla Huang1 | Olivia Supan1 | Cecilia L. Pak2 | Rahul C. Mehta1 | Elizabeth T. Makino11 Allergan Aesthetics, an AbbVie Company, Irvine, California, USA | 2SGS Stephens Inc., Richardson, Texas, USA
Correspondence: Olivia Supan (该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。)
Rahul C. Mehta is a former employee of Allergan Aesthetics, an AbbVie Company.
Received: 24 June 2024 | Revised: 21 August 2024 | Accepted: 26 August 2024
Funding: Allergan Aesthetics, an AbbVie Company, funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Illyce Nuñez, PhD of Peloton Advantage, LLC, an OPEN Health company, and funded by Allergan Aesthetics, an AbbVie Company.
Keywords: acne vulgaris | erythema | post-inflammatory hyperpigmentation | salicylic acid
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is
properly cited.
© 2024 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.
Pimpa Tantanasrigul1 | Apinya Sripha1 | Bunchai Chongmelaxme21
Department of Medical Services, Ministry of Public Health, Institute of Dermatology, Bangkok, Thailand | 2Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
Correspondence: Bunchai Chongmelaxme (该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。)
Received: 5 July 2024 | Accepted: 22 August 2024
Funding: The authors received no specific funding for this work.
Keywords: alpha-arbutin 5% | efficacy | kojic acid 2% | melasma | safety | triple combination cream
ABSTRACT
Background: While the gold standard treatment for melasma is triple combination cream (TCC), arbutin and kojic acid demonstrate their benefits and may be used as an alternative.
Aims: To investigate the efficacy of cream containing alpha-arbutin 5% and kojic acid 2% (AAK) compared with TCC for melasma treatment.
Patients/Methods: A split-faced, randomized study was conducted among 30 participants with melasma, and all were randomized to receive AAK or TCC on each side of their face for 12-week along with 4-week follow-up period. The melanin index (MI), modified Melasma Area Severity Index (mMASI), and physician global assessment (PGA) scores were used to measure the effectiveness of interventions. Recurrence of melasma after treatment discontinuation was evaluated by MI and mMASI. Patient satisfactions and adverse effects were also evaluated. In the analysis, the mean difference (MD) was used for MI and mMASI, while Wilcoxon signed-rank test was for the PGA scores, adverse effects, and patient satisfaction.
Results: The MD of MI and mMASI scores were not different between groups (mMASI [p=0.344] and MI [p=0.268]). The PGA scores only showed improvement on the TCC-treated side (p=0.032). Compared to the AKK group, the subjects with TCC showed higher severity of recurrence (MI [p=0.004] and mMASI [p=0.045]). No difference in patient satisfaction score between the groups, but erythema and stinging were higher in the TCC group.
Conclusions: The AAK cream appeared to be effective for melasma treatment, highlighting a lower recurrent rate and fewer adverse events than standard therapy.
Trial Registration: thaiclinicaltrials.org: TCTR20230124004
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。